Pan-Cancer Analysis Reveals SOX2 As a Promising Prognostic and Immunotherapeutic Biomarker Across Various Cancer Types, Including Pancreatic Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2024 Jan 2

PMID 38164286

Authors

Yuntao Ding

Huizhi Wang

Qiaowei Wang

Han Jiang

Zhangzuo Li

Zhengyue Yu

Qi Wang

Min Xu

Affiliations

Soon will be listed here.

Abstract

SOX2 is associated with the initiation, growth, and progression of various tumors and is related to stem cells. However, further studies of SOX2 in a pan-cancer context are warranted. In this study, we obtained pan-cancer and clinical data from TCGA, GTEx, STRING, and TISIDB databases and we analyzed the relationship between SOX2 expression levels and changes in gene diagnostics and survival prognosis. Additionally, we compared the expression levels of SOX2 in pancreatic cancer and healthy pancreatic tissues using Wilcoxon's rank-sum test. Functional enrichment analysis was conducted to identify potential signaling pathways and biological functions. To determine the prognostic value, we used the area under the curve (AUC) and Cox regression analysis. We further developed nomograms to predict overall survival at 1, 6, and 12 months after cancer diagnosis. Moreover, we assessed immune cell infiltration using single-sample gene set enrichment analysis. The methylation status of SOX2 was analyzed using the UALCAN and MethSurv databases. Furthermore, we verified the differential expression of SOX2 in pancreatic cancer cell lines by western blotting and quantitative polymerase chain reaction. We also confirmed the effect of SOX2 on the invasion and migration of pancreatic cancer cells using transwell and scratch assays. The biological effects were confirmed using a clone-formation assay. Our findings suggest that SOX2 is highly expressed in various tumor tissues and has potential clinical significance. It can be used as a new biomarker for pancreatic adenocarcinoma and plays a crucial role in immune infiltration.

Citing Articles

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.

Xing S, Li D, Zhao Q Aging (Albany NY). 2024; 16(17):12392-12413.

PMID: 39207452 PMC: 11424578. DOI: 10.18632/aging.206096.

References

Suarez-Sanchez F, Lequerica-Fernandez P, Suarez-Canto J, Rodrigo J, Rodriguez-Santamarta T, Dominguez-Iglesias F . Macrophages in Oral Carcinomas: Relationship with Cancer Stem Cell Markers and PD-L1 Expression. Cancers (Basel). 2020; 12(7). PMC: 7408350. DOI: 10.3390/cancers12071764. View

Lovnicki J, Gan Y, Feng T, Li Y, Xie N, Ho C . LIN28B promotes the development of neuroendocrine prostate cancer. J Clin Invest. 2020; 130(10):5338-5348. PMC: 7524485. DOI: 10.1172/JCI135373. View

Huang H, Han Q, Zheng H, Liu M, Shi S, Zhang T . MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. Cell Death Dis. 2021; 13(1):13. PMC: 8688448. DOI: 10.1038/s41419-021-04474-1. View

Sirkisoon S, Carpenter R, Rimkus T, Doheny D, Zhu D, Aguayo N . TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene. 2019; 39(1):64-78. PMC: 6938539. DOI: 10.1038/s41388-019-0959-3. View

Ding Y, Feng Y, Huang Z, Zhang Y, Li X, Liu R . SOX15 transcriptionally increases the function of AOC1 to modulate ferroptosis and progression in prostate cancer. Cell Death Dis. 2022; 13(8):673. PMC: 9349193. DOI: 10.1038/s41419-022-05108-w. View

Vasquez J, Huttner A, Zhang L, Marks A, Chan A, Baehring J . SOX2 immunity and tissue resident memory in children and young adults with glioma. J Neurooncol. 2017; 134(1):41-53. PMC: 7906294. DOI: 10.1007/s11060-017-2515-8. View

He K, Gan W . Wnt/β-Catenin Signaling Pathway in the Development and Progression of Colorectal Cancer. Cancer Manag Res. 2023; 15:435-448. PMC: 10224676. DOI: 10.2147/CMAR.S411168. View

Mollaoglu G, Jones A, Wait S, Mukhopadhyay A, Jeong S, Arya R . The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. Immunity. 2018; 49(4):764-779.e9. PMC: 6197489. DOI: 10.1016/j.immuni.2018.09.020. View

Xiao Y, Yu D . Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2020; 221:107753. PMC: 8084948. DOI: 10.1016/j.pharmthera.2020.107753. View

10.

Sebestyen Z, Prinz I, Dechanet-Merville J, Silva-Santos B, Kuball J . Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2019; 19(3):169-184. DOI: 10.1038/s41573-019-0038-z. View

11.

Huang B, Lei Z, Zhang G, Li D, Song C, Li B . SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008; 112(4):1269-79. PMC: 2515142. DOI: 10.1182/blood-2008-03-147033. View

12.

Lourenco A, Coffer P . SOX4: Joining the Master Regulators of Epithelial-to-Mesenchymal Transition?. Trends Cancer. 2017; 3(8):571-582. DOI: 10.1016/j.trecan.2017.06.002. View

13.

Zhou T, Wu L, Ma N, Tang F, Yu Z, Jiang Z . SOX9-activated FARSA-AS1 predetermines cell growth, stemness, and metastasis in colorectal cancer through upregulating FARSA and SOX9. Cell Death Dis. 2020; 11(12):1071. PMC: 7736271. DOI: 10.1038/s41419-020-03273-4. View

14.

Novak D, Huser L, Elton J, Umansky V, Altevogt P, Utikal J . SOX2 in development and cancer biology. Semin Cancer Biol. 2019; 67(Pt 1):74-82. DOI: 10.1016/j.semcancer.2019.08.007. View

15.

Zhang X, Wang W, Wang Y, Zhu L, Ma L . The association of SOX2 with clinical features and prognosis in colorectal cancer: A meta-analysis. Pathol Res Pract. 2019; 216(1):152769. DOI: 10.1016/j.prp.2019.152769. View

16.

Gao Y, Zhang N, Zeng Z, Wu Q, Jiang X, Li S . LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer. Clin Transl Med. 2022; 12(4):e792. PMC: 9005924. DOI: 10.1002/ctm2.792. View

17.

Eom B, Jo M, Kook M, Ryu K, Choi I, Nam B . The lymphangiogenic factor SOX 18: a key indicator to stage gastric tumor progression. Int J Cancer. 2011; 131(1):41-8. DOI: 10.1002/ijc.26325. View

18.

Quan M, Guo Q, Liu J, Yang R, Bai J, Wang W . An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Front Cell Dev Biol. 2020; 8:287. PMC: 7221133. DOI: 10.3389/fcell.2020.00287. View

19.

Sutton C, Lalor S, Sweeney C, Brereton C, Lavelle E, Mills K . Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009; 31(2):331-41. DOI: 10.1016/j.immuni.2009.08.001. View

20.

Silva-Santos B, Mensurado S, Coffelt S . γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019; 19(7):392-404. PMC: 7614706. DOI: 10.1038/s41568-019-0153-5. View